Dr. Quay has served as Chief Executive Officer, President, and Chairman since founding Atossa Therapeutics in 2009. A specialist in Anatomic Pathology, he completed his residency at Massachusetts General Hospital (Harvard) and served on the faculty at Stanford University School of Medicine. An accomplished innovator, he holds 96 U.S. patents and developed seven FDA-approved pharmaceuticals. He earned an M.D. and Ph.D. from the University of Michigan. His board leadership is rooted in his status as a founder and his role as the principal researcher directing the clinical and regulatory advancement of the company’s pharmaceutical programs.
Experts Harpreet Singh and Steven Quay discuss FDA expedited regulatory pathways for biologics, including Fast Track, Breakthrough Therapy, RMAT, Real-Time Oncology Review, and the National Priority Voucher Pilot Program, and explain how these mechanisms can accelerate development without lowering evidentiary standards.
August 28th 2026
